Dolutegravir Sodium; Lamivudine Patent Expiration
Dolutegravir Sodium; Lamivudine is Used for the treatment of HIV infection. It was first introduced by Viiv Healthcare Co
Dolutegravir Sodium; Lamivudine Patents
Given below is the list of patents protecting Dolutegravir Sodium; Lamivudine, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Dovato | US11234985 | Antiviral therapy | Jan 24, 2031 | Viiv Hlthcare |
Dovato | US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Oct 05, 2027 | Viiv Hlthcare |
Dovato |
US8129385 (Pediatric) | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Apr 05, 2028 | Viiv Hlthcare |
Dovato | US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Dec 08, 2029 | Viiv Hlthcare |
Dovato |
US9242986 (Pediatric) | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Jun 08, 2030 | Viiv Hlthcare |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳